OnPoint Vision, Inc. Opens Phase I Enrollment of Approved IDE.


ALISO VIEJO, Calif., March 25, 2024, OnPoint Vision Inc, a privately held ophthalmic medical device company, announced open enrollment of approved Investigational Device Exemption (IDE) begin Phase I of their pivotal clinical trial of the AccuraSee™ Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with a pre-existing 6mm acrylic posterior chamber intraocular lens (IOL). The IOPCL MAG is neutral optic (Plano power) with a central +10.0D 1.8mm zone designed to magnify near images when unilaterally implanted in low vision pseudophakic subjects with inactive Age-Related Macular Degeneration (AMD) at least 6 months after cataract surgery. The IOPCL MAG was originally implanted in First in Human (FIH) study in the US under a separate Early Feasibility Study (EFS) IDE where enrollment is complete and patient follow-up is complete.

OnPoint Vision also announced completion of site selection for the FDA approved refractive EFS IDE to evaluate the initial safety and effectiveness of the AccuraSee™ IOPCL (monofocal) for secondary implantation in the capsular bag to improve near and/or intermediate vision by inducing myopia (monovision) when implanted in the non-dominant eye in up to ten (10) pseudophakic subjects following at least 6 months after previous cataract surgery. This will be the second EFS of the monofocal IOPCL, whereas the FIH study of the monofocal IOPCL was conducted in low vision subjects. This first EFS was completed and closed under a separate IDE.

CAUTION AccuraSee™ IOPCL and AccuraSee™ IOPCL MAG are Investigational devices. Limited by Federal (or United Sates) law to investigational use.

About the Technology

OnPoint was founded in 2019, the founder and inventor of this technology, Kevin J. Cady, CEO and President has been involved in innovative ophthalmic products for the past 30-years. The IOPCL (Intraocular Pseudophakic Capsular Lens), was originally designed to correct post-cataract residual refractive errors. However, it quickly became apparent that this lens platform could be used for a variety of pseudophakic refractive applications.

OnPoint Vision Sees Clear Road Ahead

OnPoint Vision has developed a 4.5 millimeter lens to help treat macular degeneration. The Food and Drug Administration initially accepted Kevin Cady’s proposal for an implantable lens to correct vision after cataract surgery. Then the

Read More »

OnPoint Vision, Inc.
6A Liberty Street, Suite 100
Aliso Viejo, CA 92656

email: info@onpoint-vision.com

phone: (949) 688-0660

President & CEO

Kevin Cady is the CEO and Founder of OnPoint Vision™, a refractive company that designs, develops & manufactures intraocular lens implants, most specifically the AccuraSee™ Intraocular Pseudophakic Contact Lens (AKA: CadyLens) designed to fine-tune the refractive error of the pseudophakic eye as well as deliver vision recovery for patients who have experienced a decline in vision due to age-related retinal pathologies.  Prior to forming OnPoint Vision™, Mr. Cady joined Refocus Group in 2015 as Vice President of Marketing & Business Development. From 2011 to 2014, Mr. Cady was the Regional Business Director for WaveTec Vision Systems, where he was responsible for the marketplace expansion of the Optiwave Refractive Analysis (ORA) system to ophthalmic surgeons. Prior to joining WaveTec Vision Systems, Mr. Cady was the Area Vice President of Sales for Bausch Lomb Surgical, after the company acquired Eyeonics. Mr. Cady has over 30 years in the ophthalmic industry theatre with extensive knowledge and experience in both the development of ophthalmic pharmacologic agents and medical device product line.

Mr. Cady has a Bachelor of Science Degree in Economics from Illinois State University. He is credentialed with over 35 patents worldwide with the  invention of the CadyLens, an Intraocular Pseudophakic Contact Lens (IOPCL) as well as related surgical instruments and medical devices.